You are here

Article Text

Article menu
Download PDFPDF
A difficult case
Hypothyroid ataxia complicating monoclonal antibody therapy

Abstract

We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the ‘immune checkpoint inhibitor’ class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.

  • neuroimmunology
  • cerebellar ataxia
  • neuroendocrinology

https://doi.org/10.1136/practneurol-2017-001713

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.